Septerna (SEPN) News
NASDAQ: SEPNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
38.61-0.59 (-1.51%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SEPN news summary
We found 5 recent headlines mentioning Septerna (SEPN): 0 in the past week and 5 in the past 30 days, most often from Nasdaq, GlobeNewswire, Seeking Alpha. For price context, SEPN is down 1.51% at $38.61. The most recent story, "Septerna Reports Q3 Results; Advances SEP-479 And SEP-204 Toward Phase 1 Milestones In 2027", was published by Nasdaq on Nov 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Septerna headlines
- Septerna Reports Q3 Results; Advances SEP-479 And SEP-204 Toward Phase 1 Milestones In 2027(RTTNews) - Septerna, Inc. (SEPN), a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, on Tuesday reported third-quarter 2026 financial results and…NasdaqSEPN, BIO.B
- Septerna, Inc. GAAP EPS of -$0.57, revenue of $18.88MSeeking Alpha
- Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial ResultsPhase 1 Clinical Trial for PTH1R Agonist SEP-479 Ongoing; SAD / MAD Data Expected in Q1 2027GlobeNewswire
- Moderna (MRNA) Q3 Earnings and Revenues Top EstimatesModerna (MRNA) delivered earnings and revenue surprises of +134.55% and +47.73%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqMRNA, SEPN
- Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual MeetingPotent, selective TSHR NAM with pre-clinical activity demonstrated across biochemical, thyroid and ocular endpointsGlobeNewswire